These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21974698)

  • 1. Influence of antiplatelet medications on bleeding events in hemodialysis patients.
    Daimon S; Terai H
    Ther Apher Dial; 2011 Oct; 15(5):454-9. PubMed ID: 21974698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet antiaggregation and hemorrhagic risk in hemodialysis].
    Sánchez Perales MC; Vázquez E; García Cortés MJ; Borrego FJ; Borrego J; Pérez del Barrio P; Liébana A; Gil JM; Viedma G; Pérez Bañasco V
    Nefrologia; 2002; 22(5):456-62. PubMed ID: 12497747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
    Lee MS; Smith SD; Galor A; Hoffman GS
    Arthritis Rheum; 2006 Oct; 54(10):3306-9. PubMed ID: 17009265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin.
    Flint S; Taylor E; Beavis J; Becker GJ; Pedagogos E
    Nephron Clin Pract; 2009; 113(1):c38-45. PubMed ID: 19590234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
    Tompkins C; Cheng A; Dalal D; Brinker JA; Leng CT; Marine JE; Nazarian S; Spragg DD; Sinha S; Halperin H; Tomaselli GF; Berger RD; Calkins H; Henrikson CA
    J Am Coll Cardiol; 2010 May; 55(21):2376-82. PubMed ID: 20488310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
    Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications after placement of an intracoronary stent: nursing implications.
    Dabbs AD; Chambers CE; Macauley K
    Am J Crit Care; 1998 Mar; 7(2):117-22. PubMed ID: 9509225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination oral antiplatelet therapy may increase the risk of hemorrhagic complications in patients with acute ischemic stroke caused by large artery disease.
    Itabashi R; Mori E; Furui E; Sato S; Yazawa Y; Fujiwara S
    Thromb Res; 2011 Dec; 128(6):541-6. PubMed ID: 21741075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
    Guthrie R
    Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Islam AM; Patel PM
    J Cardiovasc Pharmacol; 2010 Jun; 55(6):585-94. PubMed ID: 20224426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.
    Serebruany VL; Malinin AI; Ferguson JJ; Vahabi J; Atar D; Hennekens CH
    Fundam Clin Pharmacol; 2008 Jun; 22(3):315-21. PubMed ID: 18485150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy.
    Kuhli-Hattenbach C; Fischer IB; Schalnus R; Hattenbach LO
    Am J Ophthalmol; 2010 Feb; 149(2):316-321.e1. PubMed ID: 19939348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
    Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.